2007年11月16日，来自全国心血管和内分泌领域的专家汇聚北京嘉里中心，讨论ADVANCE（Action in Diabetes and Vascular Disease）最新研究结果。研讨会由顾复生教授和武阳丰教授主持，会上ADVANCE研究项目全球负责人之一Bruce Neal教...2007年11月16日，来自全国心血管和内分泌领域的专家汇聚北京嘉里中心，讨论ADVANCE（Action in Diabetes and Vascular Disease）最新研究结果。研讨会由顾复生教授和武阳丰教授主持，会上ADVANCE研究项目全球负责人之一Bruce Neal教授，做了题为“从UKPDS到ADVANCE：糖尿病与高血压治疗的新进展”的学术报告。展开更多
Background and objective:The benefit from adjuvant chemotherapy for patients treated with neoadjuvant chemoradiotherapy(NCRT)and curative surgery remains controversial,particularly among those responding well to NCRT....Background and objective:The benefit from adjuvant chemotherapy for patients treated with neoadjuvant chemoradiotherapy(NCRT)and curative surgery remains controversial,particularly among those responding well to NCRT.This retrospective study aimed to clarify the benefits of adjuvant chemotherapy in terms of the oncological outcomes of patients with ypT0–2N0 rectal cancer after NCRT and curative surgery.Methods:All patients with ypT0–2N0 rectal cancer after NCRT and curative resection between 2005 and 2014 were examined.The oncological outcomes between patients treated with adjuvant chemotherapy and those without any chemotherapy were compared.Results:The clinicopathological characteristics of 110 patients were reviewed in this study;one patient was excluded due to lack of follow-up.Of the 109 patients included,58(53.2%)underwent adjuvant chemotherapy(chemo group),whereas the remaining 51(46.8%)did not receive any chemotherapy(non-chemo group).After a median follow-up of 50 months,there were no significant differences in the 5-year overall survival(OS)or recurrence-free survival(RFS)rates between the groups(OS:92.1 vs 86.3%,P=0.375;RFS:80.9 vs 74.7%,P=0.534).Subgroup analysis also demonstrated no significant differences in 5-year OS and RFS rates between patients with ypT0N0 rectal cancer(P=0.712 and P=0.599,respectively)and those with ypT1–2N0 disease(P=0.255 and P=0.278,respectively).Conclusions:These results indicate that patients with ypT0–2N0 rectal cancer after NCRT followed by curative surgery may not derive significant benefit from adjuvant chemotherapy.However,further prospective randomized trials,with larger sample sizes,are warranted to confirm this conclusion.展开更多
文摘2007年11月16日，来自全国心血管和内分泌领域的专家汇聚北京嘉里中心，讨论ADVANCE（Action in Diabetes and Vascular Disease）最新研究结果。研讨会由顾复生教授和武阳丰教授主持，会上ADVANCE研究项目全球负责人之一Bruce Neal教授，做了题为“从UKPDS到ADVANCE：糖尿病与高血压治疗的新进展”的学术报告。
基金supported by National Key R&D Program of China(No.2017YFC0908203)and CAMS Initiative for Innovative Medicine(No.CAMS-I2M-003).
文摘Background and objective:The benefit from adjuvant chemotherapy for patients treated with neoadjuvant chemoradiotherapy(NCRT)and curative surgery remains controversial,particularly among those responding well to NCRT.This retrospective study aimed to clarify the benefits of adjuvant chemotherapy in terms of the oncological outcomes of patients with ypT0–2N0 rectal cancer after NCRT and curative surgery.Methods:All patients with ypT0–2N0 rectal cancer after NCRT and curative resection between 2005 and 2014 were examined.The oncological outcomes between patients treated with adjuvant chemotherapy and those without any chemotherapy were compared.Results:The clinicopathological characteristics of 110 patients were reviewed in this study;one patient was excluded due to lack of follow-up.Of the 109 patients included,58(53.2%)underwent adjuvant chemotherapy(chemo group),whereas the remaining 51(46.8%)did not receive any chemotherapy(non-chemo group).After a median follow-up of 50 months,there were no significant differences in the 5-year overall survival(OS)or recurrence-free survival(RFS)rates between the groups(OS:92.1 vs 86.3%,P=0.375;RFS:80.9 vs 74.7%,P=0.534).Subgroup analysis also demonstrated no significant differences in 5-year OS and RFS rates between patients with ypT0N0 rectal cancer(P=0.712 and P=0.599,respectively)and those with ypT1–2N0 disease(P=0.255 and P=0.278,respectively).Conclusions:These results indicate that patients with ypT0–2N0 rectal cancer after NCRT followed by curative surgery may not derive significant benefit from adjuvant chemotherapy.However,further prospective randomized trials,with larger sample sizes,are warranted to confirm this conclusion.
